Eyebright Medical Technology (Beijing) Future Growth
Future criteria checks 5/6
Eyebright Medical Technology (Beijing) is forecast to grow earnings and revenue by 28.1% and 27.7% per annum respectively. EPS is expected to grow by 28% per annum. Return on equity is forecast to be 18% in 3 years.
Key information
28.1%
Earnings growth rate
28.0%
EPS growth rate
| Medical Equipment earnings growth | 23.5% |
| Revenue growth rate | 27.7% |
| Future return on equity | 18.0% |
| Analyst coverage | Low |
| Last updated | 10 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,444 | 692 | 602 | 647 | 5 |
| 12/31/2025 | 1,909 | 534 | 360 | 529 | 5 |
| 12/31/2024 | 1,430 | 382 | 132 | 359 | 2 |
| 6/30/2024 | 1,230 | 349 | -225 | 255 | N/A |
| 3/31/2024 | 1,072 | 328 | -208 | 239 | N/A |
| 12/31/2023 | 951 | 304 | -158 | 213 | N/A |
| 9/30/2023 | 806 | 287 | -79 | 175 | N/A |
| 6/30/2023 | 713 | 272 | -76 | 200 | N/A |
| 3/31/2023 | 638 | 252 | -25 | 236 | N/A |
| 12/31/2022 | 579 | 233 | -21 | 250 | N/A |
| 9/30/2022 | 549 | 229 | -51 | 280 | N/A |
| 6/30/2022 | 500 | 203 | -58 | 255 | N/A |
| 3/31/2022 | 480 | 194 | -71 | 230 | N/A |
| 12/31/2021 | 433 | 171 | -92 | 219 | N/A |
| 9/30/2021 | 416 | 168 | -10 | 217 | N/A |
| 6/30/2021 | 376 | 150 | 17 | 201 | N/A |
| 3/31/2021 | 331 | 129 | -19 | 160 | N/A |
| 12/31/2020 | 273 | 97 | 5 | 123 | N/A |
| 9/30/2020 | 237 | 86 | -9 | 83 | N/A |
| 6/30/2020 | 204 | 68 | -23 | 43 | N/A |
| 3/31/2020 | 178 | 53 | -93 | 44 | N/A |
| 12/31/2019 | 195 | 67 | -91 | 50 | N/A |
| 12/31/2018 | 127 | 20 | -40 | 32 | N/A |
| 12/31/2017 | 75 | -4 | N/A | 4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688050's forecast earnings growth (28.1% per year) is above the savings rate (2.9%).
Earnings vs Market: 688050's earnings (28.1% per year) are forecast to grow faster than the CN market (22.9% per year).
High Growth Earnings: 688050's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688050's revenue (27.7% per year) is forecast to grow faster than the CN market (13.1% per year).
High Growth Revenue: 688050's revenue (27.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688050's Return on Equity is forecast to be low in 3 years time (18%).